WO1996020936A1 - Nouveaux derives de thiazolidin-4-one - Google Patents

Nouveaux derives de thiazolidin-4-one Download PDF

Info

Publication number
WO1996020936A1
WO1996020936A1 PCT/KR1995/000183 KR9500183W WO9620936A1 WO 1996020936 A1 WO1996020936 A1 WO 1996020936A1 KR 9500183 W KR9500183 W KR 9500183W WO 9620936 A1 WO9620936 A1 WO 9620936A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
compound
definded
following formula
alkyl group
Prior art date
Application number
PCT/KR1995/000183
Other languages
English (en)
Inventor
Pyeong-Uk Park
Sungsoo Pyo
Ki-Seung Lee
Jongsik Gam
Jin Heung Sung
Jung Soo Park
Don Soo Park
Keun Ho Ryu
Jeong Ho Park
Original Assignee
Sunkyong Industries Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunkyong Industries Co., Ltd. filed Critical Sunkyong Industries Co., Ltd.
Priority to JP8520863A priority Critical patent/JPH09503792A/ja
Priority to AU43173/96A priority patent/AU4317396A/en
Priority to EP95941921A priority patent/EP0748317A1/fr
Publication of WO1996020936A1 publication Critical patent/WO1996020936A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems

Definitions

  • the present invention relates to novel thiazolidin-4-one derivatives having the following formula(I), which inhibit platelet-activating factor and/or 5-lipoxygenase for the prevention or treatment of inflammatory and allergic disorders mediated by platelet-activating factor and/or leukotrienes, and to pharmaceutical compositions containing these compounds, and to the use thereof to inhibit PAF and/or leukotriene.
  • a process for preparing these compounds is also included in the present invention.
  • n, T, Q, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are respectively defined as the below.
  • PAF-antagonistic activity-possessing compounds are very useful for treating various PAF-induced diseases, such as inflammatory diseases, allergic diseases, anaphylatic shocks, septic shocks, vascular diseases as DIC, myocardinal diseases, asthma, pulmonary edema, and adult respiratory diseases.
  • Leukotrienes like PAF, are potent lipid mediators of a variety of topical and systemic diseases and disorders.
  • a 5-lipoxygenase in cytoplasm catalyzes the conversion of arachidonic acid to leukotriene A4 which is the precursor of leukotriene B4 and C4.
  • Leukotriene B4 and C4 are oxygenated metabolites that contribute to the pathogenosis of such inflammatory disorders as arthritis, asthma, psoriasis, and thrombotic disease.
  • Leukotrienes are released concomitantly from leukocytes with PAF from a common phospholipid precursor upon cellular activation and act synergistically with PAF in many biological models.
  • N-(phenyl, pyridyl)-2-pyridyl-thiazolidin-4-one derivatives for agricultural chemicals Japanese Patent Kokai No. 145679/79
  • N-(phenyl, benzyl, cycloalkyl)-2-pyridyl-thiazolidin-4- one derivatives for agricultural chemicals Japanese Patent Kokai No. 55184/80
  • N- (carboxycyclohexylmethyl)-2-pyridyl-thiazolidin-4-one derivatives for anticomplementary acitvity Japanese Patent Application Kokai No.
  • N-(carboxymethylphenyl)-2-pyridyl-thiazolidin-4-one derivatives having anti-inflammatory and analgesic activity Japanese Patent Kokai No. 88170/82]; N-(pyrazinyl)-2-pyridyl-thiazolidin-4-one derivatives for agricultural chemicals [Japanese Patent Kokai No. 183689/83]; N-(phenyl)-2-pyridyl-thiazolidin-4-one derivatives for intermediates in synthesis [U.S. Patent No.
  • PAF and leukotrienes synthesis of new compounds which possess leukotriene or PAF inhibitory activity, and preferably compounds which possess both inhibitory activity will be very useful as active ingredients in the prevention and/or treatement of those diseases and disorders.
  • the present invention relates to the novel thiazolidin-4-one derivatives having the following formula(I), which act as PAF antagonists and/or inhibit biosynthesis of leukotrienes via the 5-lipoxygenase pathway.
  • n (), 1, 2 or 3;
  • Q is C 1 ⁇ C 10 alkyl group, phenyl group that is optionally substituted with one or more suitable substituents selected from methoxy group and nitro group, or pyridiyl group that is optionally substituted with one or more methyl group;
  • R 1 , R 2 and R 3 are independently hydrogen atom, C 1 ⁇ C 10 alkyl group, C 3 ⁇ C 6 cycloalkyl group, or phenyl group that is optionally substituted with one or more methoxy group;
  • R 4 , R 5 , R 6 , R 7 and R" are independently hydrogen atom, hydroxyl group, halogen atom, C 1 ⁇ C 10 alkyl group, C 1 ⁇ C 10 alkoxy group, nitro group, amino group that is optionally substituted with one or more suitable substituents selected from C 1 - C 10 alkyl group and C 3 ⁇ C 6 cycloalkyl group, phenyl group that is optionally substituted with one or more suitable substituents selected from methoxy
  • R 9 is hydrogen atom, phenyl group that is optionally substituted with one or more suitable substituents selected from C 1 ⁇ C 6 alkyl group and C 1 ⁇ C 6 alkoxy group, or a pyridyl group
  • R 10 is hydrogen atom, C 1 ⁇ C 10 alkyl group, or C 1 ⁇ C 4 alkanoyl group
  • R 11 is C 1 ⁇ C 10 alkyl group, C 1 ⁇ C 10 alkoxy group, or amino group that is optionally substituted with one or more suitable substituents selected from C 1 ⁇ C 10 alkyl group and C 3 ⁇ C 6 cycloalkyl group
  • R 12 is C 1 ⁇ C 10 alkyl group or phenyl group
  • R 13 is hydrogen atom, C 1 ⁇ C 10 alkyl group, or C 1 ⁇ C I0 alkanoyl group
  • R 14 is hydrogen atom or C 1
  • the present invention also includes pharmaceutically acceptable salts of the formula(I), including, for example, salts with mineral acids such as, e.g., hydrochloric acid, hydrobromic acid, phosphoric acid or sulfuric acid, or salts with organic carboxylic acid such as, e.g., formic acid, acetic acid, malic acid, citric acid, maleinic acid, fumalic acid or tartaric acid.
  • mineral acids such as, e.g., hydrochloric acid, hydrobromic acid, phosphoric acid or sulfuric acid
  • organic carboxylic acid such as, e.g., formic acid, acetic acid, malic acid, citric acid, maleinic acid, fumalic acid or tartaric acid.
  • the compounds according to the invention may be existed geometrical or optical isomerism.
  • the present invention includes isomer in each case the isomerism and hydrate of the compounds.
  • Novel compounds(I) of the present invention can be prepared by reacting compound of formula(II)
  • T and Q are defined as in the formula(I);
  • n, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are defined as in the formual(I);
  • n, T, Q, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are defined as in formula(I).
  • reaction of compound(II) with compound(III) is preferably carried out in a suitable solvent which at least one selected from inert organic solvents such as, e.g., tetrahydrofuran, benzene, toluene, dichloromethane or dichloroethane, and polar organic solvents such as, e.g., methanol, ethanol, dimethylsulfoxide, N,N-dimethylformamide or acetic acid.
  • inert organic solvents such as, e.g., tetrahydrofuran, benzene, toluene, dichloromethane or dichloroethane
  • polar organic solvents such as, e.g., methanol, ethanol, dimethylsulfoxide, N,N-dimethylformamide or acetic acid.
  • the basic medium for the reaction of compound (II) and (III) is preferably metal hydride such as, e.g., sodium hydride, potassium hydride or calcium hydride, lithium diisopropylamide, methyl lithium, butyl lithium, phenyl lithium, sodium methoxide, sodium ethoxide, sodium acetate, sodium hydroxide, potassium hydroxide, or organic base such as, e.g., triethyl amine, piperidine or morpholine, etc.
  • metal hydride such as, e.g., sodium hydride, potassium hydride or calcium hydride, lithium diisopropylamide, methyl lithium, butyl lithium, phenyl lithium, sodium methoxide, sodium ethoxide, sodium acetate, sodium hydroxide, potassium hydroxide, or organic base such as, e.g., triethyl amine, piperidine or morpholine, etc.
  • reaction mixture can be reacted with an acid or alkali to immediately obtain compound of the formula(I).
  • n, T, Q, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are defined as the above.
  • Suitable preferred acids are inorganic acid such as, e.g., hydrochloric acid, hydrochloric acid/methanol or hydrochloric acid/ethanol, or organic acid such as, e.g., acetic acid or p-toluenesulfonic acid, etc..
  • suitable preferred alkalis are sodium hydroxide, potassium hydroxide, sodium methoxide or sodium ethoxide, etc..
  • the formula(I-1) as intermidate may be isolated from the reaction mixture in a high yield.
  • the compound of formula(I) can be prepared by reacting compound of formula(II-1)
  • T and Q are defined as in the formula(I), and X is halogen atom;
  • n, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are defined as in the formula(I);
  • n, T, Q, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are defined as in the formula(I); and reacting the compound of formula(I-1) with the said acid or alkali.
  • the present invention relates to process for preparing compound of formula(II-1)
  • T and Q are as defined in formula(I), and X is halogen atom;
  • T and Q are defined as in formula(I);
  • halide such as, e.g., bromine, iodine, chlorine, N-bromosuccinimide, N-bromophthalimide, N-chlorosuccinimide or N-chlorophthalimide in an organic solvents such as, e.g., ether, tetrahydrofuran, chloroform, carbon tetrachloride, dichloromethane, benzene, toluene, dimethyl form amide or etc. at 0 oC to reflux temperature.
  • organic solvents such as, e.g., ether, tetrahydrofuran, chloroform, carbon tetrachloride, dichloromethane, benzene, toluene, dimethyl form amide or etc. at 0 oC to reflux temperature.
  • the present invention relates to process for preparing compound of formula(II)
  • T and Q are defined as in formula(I);
  • reaction mixture was cooled to 0 oC and added methanol (10 mL). When no more evolution of hydrogen gas the reaction mixture was warmed to room temperature added water(2() mL) and extracted with ethyl acetate(2 ⁇ 100 mL).
  • reaction mixture was neutralized with saturated sodium bicarbonate solution and extracted with ethyl acetate(3 ⁇ 30 mL).
  • the combined organic phase was dried over anhydrous magnesium sulfate, filtered, and evaporated to dryness.
  • the residue was dissolved in 30% HCl-ethanol solution(5 mL), stirred for 3 h and then neutralized with saturated sodium bicarbonate solution and extracted with ethyl acetate
  • reaction mixture was cooled to 0 oC and added methanol(4 mL). When no more evolution of hydrogen gas the reaction mixture was warmed to room temperature added water( 10 mL), and extracted with ethyl acetate(2 ⁇ 50 mL).
  • the present invention further relates to pharmaceutical compositions containing these compounds or acceptable salts thereof and the use of these compounds as antagonist of the PAF and/or inhibitor of the leukotriene.
  • compounds of the present invention possess activity of PAF-antagonist and/or leukotriene-inhibition.
  • compounds of the invention may be used for the treatment and prophylaxis of diseases mediated or effected by PAF and leukotriene.
  • the typical diseases for which the compounds of the present invention may be used as a therapeutic and propylactic agent include inflammation (for example, arthritis, nephritis), circulatory diseases(for example, shock, thrombosis, transplant rejection, cerebral anemia, etc.) and allergic diseases (for example, asthma, psoriasis).
  • the compounds according to the invention, as well as the pharmaceutically acceptable salts thereof, have potent PAF-antagonistic and leukotriene-inhibitory activity.
  • the novel compounds may be used in pharmaceutical composition comprising a pharmaceutically effective amount of one of the compounds defined above and a pharmaceutically acceptable carrier.
  • the inventive compounds are particularly useful as anti-allergic agents, anti-asthmatic agents, anti-psoriasis agents, anti-anaphylactic shock agents, anti-septic shock agents, anti-arthritic agents, anti-nephritic agents, anti-thromboplastic agents, anti-transplant rejection agents and anti-cerebral anemic agents.
  • Solid or liquid pharmaceutically acceptable carriers may also be employed.
  • Solid carriers include starch, lactose, calcium sulphate dihydrate, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate and stearic acid.
  • Liquid carriers include syrup, peanut oil, olive oil, saline solution and water.
  • the carrier or diluent may include any prolonged release material, such as glyceryl monostearate or glyceryl distearate, alone or with wax.
  • a liquid carrier When a liquid carrier is used, the preparation may be in the form of a syrup, elixir, emulsion, soft gelatin capsule, sterile injectable liquid(e.g. solution) or a nonaqueous or aqueous liquid suspension.
  • the pharmaceutical preparations are prepared conventional techniques of the pharmaceutical chemist.
  • Compounds according to the present invention may be administrated orally topically, parenterally, by inhalation spray or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles.
  • parenteral as used herein includes subcutaneous injections, intravenous injection, intramuscular injection, intrasternal injection or infusion techniques.
  • An examplary daily dosage employed depends on the type of disease, the degree of symptom and age.
  • the dosage levels of the compound in the above-indicated compositions may, of course, be varied and may conveniently be between about 0.01mg to about 200 mg per kilogram of the weight.
  • compositions containing compounds according to the invention may be in any form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispensable powders or granules, emulsion, hard or soft capsules, syrups or elixirs.
  • the tablets, capsules and the like may also contain a binder such as, e.g., lactose, saccharose, sorbitol, mannitol, starch, amylopectin, cellulose or gelatin; excipients such as, e.g., dicalcium phosphate; a disintegrating agent such as, e.g., com starch or potato starch; a lubricant such as, e.g., magnesium stearate, calcium stearate, sodium stearylfumalate or polyethylene glycol wax.
  • a liquid carrier such as e.g., a fatty oil.
  • active compounds according to the present invention may also be administered parenterally.
  • a solution or suspension of the active compounds may be prepared in water, optionally mixed with stabilizer or buffering agents.
  • the dosages for parenteral administration are preferably as ampule or vial type.
  • active compounds according to the invention may also be administered by any known process of administrating the dose including topically, for example, an ointment, cream, jelly, solution, suspension or pachydematous patch; rectally, for example, suppository; intranasally or intrathoracally by inhalation spray.
  • the present invention provides pharmaceutical compositions comprising a pharmaceutically effective amount of thiazolidin-4-one derivatives and a pharmaceutically acceptable salt thereof.
  • the present invention also provides the pharmaceutical uses of these compounds and compositions, especially for the prevent or treatment of various PAF- and/or leukotriene- induced diseases,
  • Pharmacology Example 1 PAF-induced rabbit platelet aggregation.
  • Platelet rich plasma was obtained by centrifugation of blood at 150 g for 10 min at room temperature. The number of platelets was adjusted to 3 ⁇ 10 8 platelets/mL with platelet poor plasma. Platelet aggregation was monitored by continuous recording of light transmission in a dual-channel aggregometer(Chrono-Log 560-VS) coupled with a two channel recorder(Chrono-Log 707). Stirred PRP was treated with various concentration of test compounds or vehicle(0.5 % DMSO) for 2 min and then PAF(5 ⁇ 10 -9 M) was added to induce platelet aggregation.
  • Inhibition values were calculated by comparing the extent of aggregation obtainted in the presence of the vehicle alone(0.5 % DMSO) and in the presence of a test compound. Log concentration-response curves were generated and the IC 50 values were determined by regression analysis.
  • a suspension of rat basophillic leukemia-1 cell in phosphoric acid buffer solution with a concentration of 5 ⁇ 10 6 /mL was allowed at 37oC for 5 min and added the compound of thiazolidin-4-one. After allowed for 5 min, to the mixture was added arachidonic acid(25 ⁇ l/mL) and calcium ionophoie A23187(1 ⁇ l/mL). After allowed for 15 min, the reaction mixture was quenched with 0.1N cooled hydrochloric acid and centrifuged with 3,300 rpm for 5 min. The supernatant solution was extracted with ethyl acetate and concentrated under nitrogen gas. The residue was dissolved in mobile phase and a amount of LTB 4 was determined with HPLC.
  • Table 7 lists result from this assay for inhibition of PAF-induced rabbit platelet aggregation and of LTB 4 biosynthesis for illustrative examples of the compounds of this invention.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des nouveaux dérivés de thiazolidin-4-one de la formule (I), qui ont pour effet d'inhiber le facteur d'activation des plaquettes sanguines et/ou la 5-lipoxygénase dans le traitement prophylactique ou clinique des pathologies inflammatoires et allergiques induites par le facteur d'activation des plaquettes sanguines et/des leucotriènes. L'invention concerne également des compositions pharmaceutiques à base de ces composés ainsi que leur utilisation pour inhiber le facteur d'activation des plaquettes sanguines et/ou les leucotriènes. Elle comprend en outre un procédé destiné à la préparation de ces composés, qui est représenté par la formule (I) dans laquelle n, T, Q, R?1, R2, R3, R4, R5, R6, R7 et R8¿ ont chacun la notation mentionnée dans la description.
PCT/KR1995/000183 1994-12-29 1995-12-29 Nouveaux derives de thiazolidin-4-one WO1996020936A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP8520863A JPH09503792A (ja) 1994-12-29 1995-12-29 新規なチアゾリジン−４−オン誘導体
AU43173/96A AU4317396A (en) 1994-12-29 1995-12-29 Novel thiazolidin-4-one derivatives
EP95941921A EP0748317A1 (fr) 1994-12-29 1995-12-29 Nouveaux derives de thiazolidin-4-one

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR19940038787 1994-12-29
KR1994/38787 1994-12-29

Publications (1)

Publication Number Publication Date
WO1996020936A1 true WO1996020936A1 (fr) 1996-07-11

Family

ID=19405013

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR1995/000183 WO1996020936A1 (fr) 1994-12-29 1995-12-29 Nouveaux derives de thiazolidin-4-one

Country Status (8)

Country Link
EP (1) EP0748317A1 (fr)
JP (1) JPH09503792A (fr)
KR (1) KR960022486A (fr)
CN (1) CN1142227A (fr)
AU (1) AU4317396A (fr)
CA (1) CA2184174A1 (fr)
HU (1) HU9602263D0 (fr)
WO (1) WO1996020936A1 (fr)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999062891A1 (fr) * 1998-06-05 1999-12-09 Icagen, Inc. Inhibiteurs des canaux de potassium
WO2000063197A1 (fr) * 1999-04-19 2000-10-26 Sumitomo Pharmaceuticals Company, Limited Derive d'acide hydroxamique
US6174908B1 (en) 1999-05-10 2001-01-16 Icagen, Inc. Potassium channel inhibitors
US6506751B1 (en) 1999-11-12 2003-01-14 Millennium Pharmaceuticals, Inc. Thiazolidinone compounds useful as chemokine inhibitors
US6713477B1 (en) 2000-04-19 2004-03-30 Sumitomo Pharmaceuticals Company, Limited Hydroxamic acid derivatives
WO2005054215A1 (fr) * 2003-11-21 2005-06-16 Actelion Pharmaceuticals Ltd Derives de 5-(benz-(z)-ylidene)-thiazolidine-4-one utilises comme agent immunodepresseurs
US7026344B2 (en) * 2000-08-15 2006-04-11 South Alabama Medical Science Foundation Treating sickle cell disease
US7078431B2 (en) 2000-06-20 2006-07-18 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders
US7094801B2 (en) 2001-12-19 2006-08-22 Atherogenics, Inc. Chalcone derivatives and their use to treat diseases
US7173129B2 (en) 2003-06-06 2007-02-06 Athero Genics, Inc. Sulfonamide-substituted chalcone derivatives and their use to treat diseases
US7598240B2 (en) 2004-03-02 2009-10-06 Dainippon Sumitomo Pharma Co., Ltd. Benzothiazin-3-one compound and intermediate therefor
US7629375B2 (en) 2001-07-23 2009-12-08 Johnson & Johnson Consumer Companies, Inc. Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods
US8263780B2 (en) 2006-11-23 2012-09-11 Actelion Pharmaceuticals Ltd. Process for the preparation of 2-imino-thiazolidin-4-one derivatives
USRE43833E1 (en) 2003-11-21 2012-11-27 Actelion Pharmaceuticals Ltd. Thiazolidin-4-one derivatives
US8912340B2 (en) 2006-11-23 2014-12-16 Actelion Pharmaceuticals Ltd. Process for the preparation of 2-imino-thiazolidin-4-one derivatives
US9340518B2 (en) 2012-08-17 2016-05-17 Actelion Pharmaceuticals Ltd. Process for the preparation of (2Z,5Z)-5-(3-chloro-4-((R)-2,3-dihydroxypropdxy)benzylidene)-2-(propylimino)-3-(o-tolyl)thiazolidin-4-one and intermediate used in said process
WO2021066608A1 (fr) * 2019-10-02 2021-04-08 주식회사 클로소사이언스 Composé destiné à induire l'expression d'un gène klotho anti-âge et son utilisation

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR970032857A (ko) * 1995-12-29 1997-07-22 김준웅 약제 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0292305A1 (fr) * 1987-05-22 1988-11-23 Sumitomo Pharmaceuticals Company, Limited Dérivés de thiazolidine-4-one et leurs sels d'addition
EP0316723A1 (fr) * 1987-11-20 1989-05-24 Hoechst-Roussel Pharmaceuticals Incorporated 3-[4(1-substitué-4-pipérazinyl)butyl]-4-thiazolidinones procédé de préparation et leur utilisation comme médicaments
JPH01190679A (ja) * 1988-01-22 1989-07-31 Sumitomo Pharmaceut Co Ltd 光学活性な新規チアゾリジン−４−オン　誘導体およびその酸付加塩

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0292305A1 (fr) * 1987-05-22 1988-11-23 Sumitomo Pharmaceuticals Company, Limited Dérivés de thiazolidine-4-one et leurs sels d'addition
EP0316723A1 (fr) * 1987-11-20 1989-05-24 Hoechst-Roussel Pharmaceuticals Incorporated 3-[4(1-substitué-4-pipérazinyl)butyl]-4-thiazolidinones procédé de préparation et leur utilisation comme médicaments
JPH01190679A (ja) * 1988-01-22 1989-07-31 Sumitomo Pharmaceut Co Ltd 光学活性な新規チアゾリジン−４−オン　誘導体およびその酸付加塩

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Vol. 109, No. 25, 19 December 1988, (Columbus, Ohio, USA), page 847, Abstract No. 230870g, SINGH, H. et al.: "Intramolecular Chemo-Selective Heterocyclization of 4-Oxothiazolidin-5-yl N-Aryldithiocarbamates of Fungitoxic 1,3-Dithiolo-, 1,3-Oxathiolo-, and Thiazolothiazoles"; & INDIAN J. CHEM. SECT. B, 1987, 26B(12), 1200-2, (Eng). *
CHEMICAL ABSTRACTS, Vol. 112, No. 7, 12 February 1990, (Columbus, Ohio, USA), page 772, Abstract No. 55851q, ENOMOTO, M. et al.: "Optically Active Thiazolidin-4-Ones as Platelet Activating Factor (PAF) Antagonists"; & JP,A,01 190 679. *
CHEMICAL ABSTRACTS, Vol. 112, No. 9, 26 February 1990, (Columbus, Ohio, USA), page 785, Abstract No. 77014w, ZALESKA, B. et al.: "Substitution Reactions of 2-(Aroylmethylidene)Thiazolidin-4-One Derivatives"; & J. PRAKT. CHEM., 1989, 331(1), 55-60, (Eng). *
CHEMICAL ABSTRACTS, Vol. 113, No. 11, 10 September 1990, (Columbus, Ohio, USA), page 411, Abstract No. 94650p, PISCOPO, E. et al.: "Studies on Heterocyclic Compounds: 1,3-Thiazolidin-4-One Derivatives. IV. Biological Activity of Variously Substituted 2,3-Diaryl-1,3-Thiazolidin-4-Ones"; & BOLL.-SOC. ITAL. BIOL. SPER., 1989, 65(9), 853-9, (Eng). *
CHEMICAL ABSTRACTS, Vol. 114, No. 23, 10 June 1991, (Columbus, Ohio, USA), page 870, Abstract No. 229205r, DUNN, A.D. et al.: "Sulfur Analogs of Deoxyvasicinone. Part 5. Synthesis of Methylated Analogs"; & Z. CHEM., 1990, 30(8), 288-9, (Eng). *
CHEMICAL ABSTRACTS, Vol. 76, No. 11, 13 March 1972, (Columbus, Ohio, USA), page 460, Abstract No. 59509v, SNIDER, R.H. et al.: "Friedel-Crafts Reaction with 5-Arylidene-4-Thiazolidinones"; & INT. J. SULFUR CHEM., Part A 1971, 1(3), 191-6, (Eng). *
CHEMICAL ABSTRACTS, Vol. 84, No. 25, 21 June 1976, (Columbus, Ohio, USA), page 566, Abstract No. 180117j, ASTIK, R.R. et al.: "Studies in Thiazolidinones, Part 1"; & J. INDIAN CHEM. SOC., 1975, 52(11), 1071-2, (Eng). *
CHEMICAL ABSTRACTS, Vol. 85, No. 7, 16 August 1976, (Columbus, Ohio, USA), page 521, Abstract No. 46484u, ASTIK, R.R. et al.: "Studies on Thiazolidionones, Part II"; & J. INDIAN CHEM. SOC., 1976, 53(3), 272-3, (Eng). *
CHEMICAL ABSTRACTS, Vol. 92, No. 13, 31 March 1980, (Columbus, Ohio, USA), page 653, Abstract No. 110910d, PANDYA, U.H. et al.: "Studies on Thiazolidinones. Part VII"; & J. INST. CHEM. (INDIA), 1979, 51(3), 129-30, (Eng). *
CHEMICAL ABSTRACTS, Vol. 96, No. 21, 24 May 1982, (Columbus, Ohio, USA), page 704, Abstract No. 181185q, DASH, B. et al.: "Thiazolidone Derivatives"; & J. INDIAN CHEM. SOC., 1981, 58(12), 1184-6, (Eng). *

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395730B1 (en) 1998-06-05 2002-05-28 Icagen, Inc. Potassium channel inhibitors
WO1999062891A1 (fr) * 1998-06-05 1999-12-09 Icagen, Inc. Inhibiteurs des canaux de potassium
WO2000063197A1 (fr) * 1999-04-19 2000-10-26 Sumitomo Pharmaceuticals Company, Limited Derive d'acide hydroxamique
US6174908B1 (en) 1999-05-10 2001-01-16 Icagen, Inc. Potassium channel inhibitors
US6506751B1 (en) 1999-11-12 2003-01-14 Millennium Pharmaceuticals, Inc. Thiazolidinone compounds useful as chemokine inhibitors
US6713477B1 (en) 2000-04-19 2004-03-30 Sumitomo Pharmaceuticals Company, Limited Hydroxamic acid derivatives
US7078431B2 (en) 2000-06-20 2006-07-18 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders
US7026344B2 (en) * 2000-08-15 2006-04-11 South Alabama Medical Science Foundation Treating sickle cell disease
US7629375B2 (en) 2001-07-23 2009-12-08 Johnson & Johnson Consumer Companies, Inc. Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods
US7094801B2 (en) 2001-12-19 2006-08-22 Atherogenics, Inc. Chalcone derivatives and their use to treat diseases
US7173129B2 (en) 2003-06-06 2007-02-06 Athero Genics, Inc. Sulfonamide-substituted chalcone derivatives and their use to treat diseases
EP2295418A1 (fr) * 2003-11-21 2011-03-16 Actelion Pharmaceuticals Ltd. Dérivés de 5-(benz-(z)-ylidène)-thiazolidin-4-one comme agents immunosuppresseurs
US8524752B2 (en) 2003-11-21 2013-09-03 Actelion Pharmaceuticals Ltd. Thiazolidin-4-one derivatives
US7626037B2 (en) 2003-11-21 2009-12-01 Actelion Pharmaceuticals Ltd. Thiazolidin-4-one derivatives
WO2005054215A1 (fr) * 2003-11-21 2005-06-16 Actelion Pharmaceuticals Ltd Derives de 5-(benz-(z)-ylidene)-thiazolidine-4-one utilises comme agent immunodepresseurs
US7875726B2 (en) 2003-11-21 2011-01-25 Actelion Pharmaceuticals Ltd. Thiazolidin-4-one derivatives
US9000018B2 (en) 2003-11-21 2015-04-07 Actelion Pharmaceuticals, Ltd Thiazolidin-4-one-derivatives
US7435828B2 (en) 2003-11-21 2008-10-14 Actelion Pharmaceuticals Ltd. Thiazolidin-4-one derivatives
USRE45174E1 (en) 2003-11-21 2014-09-30 Actelion Pharmaceuticals Ltd. Thiazolidin-4-one derivatives
US8273779B2 (en) 2003-11-21 2012-09-25 Actelion Pharmaceuticals Ltd. Thiazolidin 4-one derivatives
USRE43728E1 (en) 2003-11-21 2012-10-09 Actelion Pharmaceuticals Ltd. Thiazolidin-4-one derivatives
USRE43833E1 (en) 2003-11-21 2012-11-27 Actelion Pharmaceuticals Ltd. Thiazolidin-4-one derivatives
US7879843B2 (en) 2004-03-02 2011-02-01 Dainippon Sumitomo Pharma Co., Ltd. Benzothiazin-3-one compound and intermediate therefor
US7598240B2 (en) 2004-03-02 2009-10-06 Dainippon Sumitomo Pharma Co., Ltd. Benzothiazin-3-one compound and intermediate therefor
US8263780B2 (en) 2006-11-23 2012-09-11 Actelion Pharmaceuticals Ltd. Process for the preparation of 2-imino-thiazolidin-4-one derivatives
US8912340B2 (en) 2006-11-23 2014-12-16 Actelion Pharmaceuticals Ltd. Process for the preparation of 2-imino-thiazolidin-4-one derivatives
US9340518B2 (en) 2012-08-17 2016-05-17 Actelion Pharmaceuticals Ltd. Process for the preparation of (2Z,5Z)-5-(3-chloro-4-((R)-2,3-dihydroxypropdxy)benzylidene)-2-(propylimino)-3-(o-tolyl)thiazolidin-4-one and intermediate used in said process
WO2021066608A1 (fr) * 2019-10-02 2021-04-08 주식회사 클로소사이언스 Composé destiné à induire l'expression d'un gène klotho anti-âge et son utilisation

Also Published As

Publication number Publication date
KR960022486A (ko) 1996-07-18
HU9602263D0 (en) 1996-10-28
JPH09503792A (ja) 1997-04-15
CN1142227A (zh) 1997-02-05
EP0748317A1 (fr) 1996-12-18
AU4317396A (en) 1996-07-24
CA2184174A1 (fr) 1996-07-11

Similar Documents

Publication Publication Date Title
WO1996020936A1 (fr) Nouveaux derives de thiazolidin-4-one
DE69717160T2 (de) Thienotriazolodiazepinverbindungen und ihre medizinischen anwendungen
US5231101A (en) Benzo[5,6]cyclohepta[1,2-B]pyridine derivatives and antiallergic agents comprising same
UA44332C2 (uk) Похідні 2(1h)-хінолінону як антагоністи серотоніну, спосіб їх одержання (варіанти), медичний препарат та фармацевтична композиція на їх основі
GB2216517A (en) 1-(3-aryl-prop-2-enyl)-4-tricyclyl-piperazines
DE3834204A1 (de) 4h-1-benzopyran-4-on-derivate oder deren salze, verfahren zur herstellung derselben und pharmazeutische mittel mit einem gehalt derselben als wirkstoff
EP1641758B1 (fr) Derives de diphenylpyridine, leur preparation et leur application therapeutique
JPS6157587A (ja) 縮合複素環誘導体および抗潰瘍剤
DE69032537T2 (de) Verbindungen zur Behandlung von Bauchentzündungen
FR2538392A1 (fr) Derives de type carboxamido de 5h-1,3,4-thiadiazolo (3,2-a) pyrimidine, procede pour leur preparation et composition pharmaceutique les contenant et presentant un effet analgesique et anti-inflammatoire
GB2196962A (en) Substituted 2-benzyl-mercapto-imidazoles and analogs useful as anti-inflammatory agents
JP2003522772A (ja) Ｔｎｆおよびｐｄｅ−ｉｖ阻害剤としてのベンゾチアゾール
FR2656610A1 (fr) Derives d'amino-2 phenyl-4 thiazole, leur procede de preparation et leur application therapeutique.
US4684658A (en) Anti-thrombotic ortho-condensed pyrrole derivatives, compositions, and method of use therefor
JP2707936B2 (ja) β−オキソ−β−ベンゼンプロパンチオアミド誘導体
FI93108B (fi) Menetelmä lääkeaineina käyttökelpoisten 2-bentsotiatsoliinijohdannaisten valmistamiseksi
DE69904818T2 (de) Thienodipyridinderivate, ihre herstellung und verwendung
EP0115979B1 (fr) Nouveaux dérivés du 1H,3H-pyrrolo (1,2-c) thiazole leur préparation et les médicaments qui les contiennent
DE2360550A1 (de) Indenylaethyltetrazole, -sulfonsaeuren und -phosphorsaeuren
EP0229370B1 (fr) Dérivés des esters de l'acide guanidinobenzoique, un procédé pour leur préparation et compositions pharmaceutiques les contenant
US4064244A (en) Organic compounds
JPH07252260A (ja) 新規チエノチアジン誘導体、その製造方法及びその使用方法
CS226020B2 (en) Method of preparing pyridine and pyrimidine derivatives
US4929616A (en) Novel basic-substituted 5-halo-thienoisothiazol-3(2H)-one 1,1-dioxides, a process for the preparation thereof, and pharmaceutical preparations containing these compounds
US5100911A (en) Thienyloxyalkylamine derivatives, process for their preparation and medicaments containing them

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 95191872.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR CA CN HU JP NO PL RU US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 1995941921

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2184174

Country of ref document: CA

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 1996 605206

Country of ref document: US

Date of ref document: 19961205

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1995941921

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995941921

Country of ref document: EP